Início › Doenças Autoimunes › Illinois › Chicago
Ensaios clínicos de Doenças Autoimunes em Chicago, IL
12 estudos para Doenças Autoimunes estão buscando participantes em locais em Chicago e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
RecrutandoFase 2
- University of Chicago, Chicago
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecrutandoFase 2/3
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
RecrutandoFase 2
- University of Chicago, Department of Medicine: Rheumatology, Chicago
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecrutandoFase 1
- The University of Chicago Medical Center, Chicago
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecrutandoFase 1/2
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RecrutandoFase 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecrutandoFase 2/3
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecrutandoFase 1/2
- Northwestern Memorial Hospital, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecrutandoEstudo observacional
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- e mais 2
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
RecrutandoFase 1
- Northwestern University, Chicago
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecrutandoFase 1/2
- Northwestern University, Chicago
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- University of Chicago Medical Center, Chicago
Ensaios de Doenças Autoimunes em outras cidades
- Houston, TX21 estudos
- Washington, DC19 estudos
- New York City, NY19 estudos
- Philadelphia, PA16 estudos
- Durham, NC15 estudos
- Boston, MA13 estudos
- Los Angeles, CA12 estudos
- Dallas, TX9 estudos
- Cleveland, OH8 estudos
- Milwaukee, WI8 estudos
- Atlanta, GA8 estudos
- Portland, OR8 estudos
Outros estudos em Chicago
- Câncer de Pulmão de Não Pequenas Células61 estudos
- Câncer de Mama58 estudos
- Câncer (todos os tipos)51 estudos
- Câncer Metastático45 estudos
- Câncer de Próstata45 estudos
- Obesidade41 estudos
- Câncer de Pulmão41 estudos
- Câncer de Ovário36 estudos
- Acidente Vascular Cerebral34 estudos
- Câncer Colorretal33 estudos
- Insuficiência Cardíaca31 estudos
- Sobrepeso28 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.